Mesothelioma lawyer assistance for financial recovery

About the International Mesothelioma Program
IMP was founded in 2002 by Dr. David J. Sugarbaker in response to the rising incidence of mesothelioma worldwide and the limited amount of information regarding mesothelioma treatment options. The new program's success is based on a multidisciplinary team of surgeons, pulmonologists, medical and radiation oncologists, radiologists, pathologists, nurses, basic and clinical researchers, and medical and social science professionals. The Program is built on the existing Brigham and Women's Hospital team's collaboration with professionals from Harvard School of Public Health, the Dana-Farber Cancer Institute, Massachusetts General Hospital and various medical and research professionals.

The clinical focus of IMP is to develop treatment strategies that can significantly extend the life of patients. Research conducted by the IMP involves a collaboration of basic, translational, and clinical research scientists whose aim is to understand the causative factors in the development of the disease and to translate these findings into improved theory.

About the Doctors
Dr. David J. Sugarbaker is The Richard E. Wilson Professor of Surgical Oncology at Harvard Medical School, Executive Vice-Chair of the Department of Surgery at Brigham and Women's Hospital and Chief of Thoracic Surgery at Brigham and Women's Hospital in Boston, MA. He is also the Phillip E. Lowe Senior Surgeon at the Dana-Farber Cancer Institute, He is a board certified physician and graduate of Wheaton College and Cornell University Medical School.

Dr. Sugarbaker completed his surgery residency at Brigham and Women's Hospital and his Cardiothoracic training at the Toronto General Hospital as Chief Resident in both Thoracic Surgery and Cardiac Surgery. As part of his clinical and laboratory research, Dr. Sugarbaker has primarily focused on malignant pleural mesothelioma. His specific concentrations are in mesothelioma, non-small cell lung cancer, esophageal cancer, general thoracic surgery, lung volume reduction surgery, minimally invasive surgery and video-assisted thoracic surgery (VATS). He has also been actively involved in the development of several programs including The Division of Thoracic Surgery, The Brigham Lung Transplant Program and The Thoracic Oncology Program at the DFCI/BWH.

Dr. Raphael Bueno is an Associate Professor of Surgery at Harvard Medical School and Associate Chief of Thoracic Surgery, Director of the Thoracic Intermediate Care Unit, Director of the Thoracic Intermediate Care Unit, and Director of the Photodynamic Therapy Program at Brigham and Women's Hospital and Dana-Farber Cancer Institute in Boston, MA. He is a board certified physician and graduate of Harvard University and Harvard Medical School.

Dr. Bueno has conducted extensive research on molecular diagnosis and mechanisms of carcinogenesis in malignant pleural mesothelioma. His clinical interests include mesothelioma, lung cancer, esophageal cancer, benign esophageal disorders, tracheal surgery, thymomas and minimally invasive surgery. Dr. Bueno's laboratory research objectives primarily concentrate on mesothelioma and its characteristics at the molecular level in order to design novel diagnostic and therapeutic modalities.

About the Executive Advisory Board
We are very fortunate to have the financial support of our Executive Advisory Board. Limited to 5 members, the Executive Board provides the lay perspective, representing organizations focused on and impacted by this disease. The firms of Motley Rice, LLC, of Charleston, South Carolina, (www.motleyrice.com), and Thornton & Naumes, LLP, of Boston, MA, (www.tenlaw.com) each have pledged $3 Million to support the research efforts of the International Mesothelioma Program.